Daily Sepsis Research Analysis
Three impactful sepsis studies stand out today: an informatics study shows that stratifying patients by both sepsis risk and downstream mortality effect identifies different high-priority targets than risk-only approaches; a blinded, low-cost laboratory test accurately detects the cefazolin inoculum effect in MSSA bacteremia; and a mechanistic study identifies a CMTM4–STAT2–PD-L1 axis driving macrophage apoptosis in sepsis. Together, they advance precision triage, antimicrobial decision-making,
Summary
Three impactful sepsis studies stand out today: an informatics study shows that stratifying patients by both sepsis risk and downstream mortality effect identifies different high-priority targets than risk-only approaches; a blinded, low-cost laboratory test accurately detects the cefazolin inoculum effect in MSSA bacteremia; and a mechanistic study identifies a CMTM4–STAT2–PD-L1 axis driving macrophage apoptosis in sepsis. Together, they advance precision triage, antimicrobial decision-making, and immunopathology.
Research Themes
- AI-informed risk stratification that incorporates outcome severity
- Rapid antimicrobial resistance phenotype detection impacting therapy
- Immune checkpoint–related macrophage apoptosis mechanisms in sepsis
Selected Articles
1. Reformulating patient stratification for targeting interventions by accounting for severity of downstream outcomes resulting from disease onset: a case study in sepsis.
Across two ICU cohorts, the estimated effect of sepsis on mortality was only weakly correlated with predicted sepsis onset risk, and high-risk groups overlapped by 53–67% depending on the site. Incorporating the mortality effect into stratification identified a different, older population than risk-only approaches, indicating that risk-only targeting may miss high-impact intervention candidates.
Impact: This study challenges risk-only triage by demonstrating that incorporating downstream outcome severity alters who is prioritized for intervention. It provides a scalable framework with immediate relevance to AI-driven sepsis alerts and resource allocation.
Clinical Implications: Decision support should incorporate both disease risk and estimated impact on outcomes (e.g., mortality) when prioritizing alerts and resources, potentially improving yield and equity of sepsis interventions.
Key Findings
- Sepsis risk and estimated mortality effect were weakly correlated (Spearman 0.35 at U-M; 0.31 at BIDMC).
- High-risk patients overlapped by 66.8% (U-M) and 52.8% (BIDMC) between risk-only versus risk+effect stratification.
- Including mortality effect identified an older population than risk-only stratification.
- Among sepsis cases, mortality occurred in 21.9% (U-M) and 26.3% (BIDMC).
Methodological Strengths
- Large, independent ICU cohorts with external validation (n=7,282 and n=5,942).
- Clear statistical comparison of stratification strategies including correlation analysis.
Limitations
- Retrospective observational design with potential unmeasured confounding.
- Effect estimation details and generalizability beyond ICU settings may be limited.
Future Directions: Prospective evaluation of effect-aware targeting on clinical outcomes and cost-effectiveness; integration with causal inference frameworks and fairness metrics in deployment.
OBJECTIVES: To quantify differences between (1) stratifying patients by predicted disease onset risk alone and (2) stratifying by predicted disease onset risk and severity of downstream outcomes. We perform a case study of predicting sepsis. MATERIALS AND METHODS: We performed a retrospective analysis using observational data from Michigan Medicine at the University of Michigan (U-M) between 2016 and 2020 and the Beth Israel Deaconess Medical Center (BIDMC) between 2008 and 2012. We measured the correlation between the estimated sepsis risk and the estimated effect of sepsis on mortality using Spearman's correlation. We compared patients stratified by sepsis risk with patients stratified by sepsis risk and effect of sepsis on mortality. RESULTS: The U-M and BIDMC cohorts included 7282 and 5942 ICU visits; 7.9% and 8.1% developed sepsis, respectively. Among visits with sepsis, 21.9% and 26.3% experienced mortality at U-M and BIDMC. The effect of sepsis on mortality was weakly correlated with sepsis risk (U-M: 0.35 [95% CI: 0.33-0.37], BIDMC: 0.31 [95% CI: 0.28-0.34]). High-risk patients identified by both stratification approaches overlapped by 66.8% and 52.8% at U-M and BIDMC, respectively. Accounting for risk of mortality identified an older population (U-M: age = 66.0 [interquartile range-IQR: 55.0-74.0] vs age = 63.0 [IQR: 51.0-72.0], BIDMC: age = 74.0 [IQR: 61.0-83.0] vs age = 68.0 [IQR: 59.0-78.0]). DISCUSSION: Predictive models that guide selective interventions ignore the effect of disease on downstream outcomes. Reformulating patient stratification to account for the estimated effect of disease on downstream outcomes identifies a different population compared to stratification on disease risk alone. CONCLUSION: Models that predict the risk of disease and ignore the effects of disease on downstream outcomes could be suboptimal for stratification.
2. Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.
In 200 MSSA bloodstream isolates from North and Latin America, a blinded modified nitrocefin test using ampicillin disks detected the cefazolin inoculum effect with 96% sensitivity and 91.6% specificity versus high-inoculum MIC. The assay showed 94% overall accuracy and no false positives among blaZ-negative strains, offering a low-cost, scalable tool.
Impact: Provides a practical, accurate, and inexpensive method to detect CzIE, directly informing cefazolin use in MSSA bacteremia and potentially reducing treatment failures.
Clinical Implications: Clinical microbiology labs can adopt this rapid screen to identify CzIE and guide antibiotic selection (e.g., opting for anti-staphylococcal penicillins when CzIE is present) to optimize outcomes.
Key Findings
- CzIE prevalence among 200 MSSA bloodstream isolates was 53% (105/200).
- Modified nitrocefin test achieved 96% sensitivity, 91.6% specificity, and 94% accuracy versus high-inoculum MIC.
- No false positives were observed among blaZ-negative MSSA strains.
- Whole-genome sequencing enabled performance assessment across BlaZ types.
Methodological Strengths
- Blinded comparison against a defined gold standard (high-inoculum MIC).
- Inclusion of isolates from multiple regions and whole-genome sequencing characterization.
Limitations
- Laboratory validation without direct linkage to patient-level outcomes.
- Focused on MSSA; generalizability to other organisms or settings may be limited.
Future Directions: Prospective clinical studies linking CzIE detection to antibiotic choices and outcomes; implementation research in low-resource settings; automation/integration into lab workflows.
BACKGROUND: The cefazolin inoculum effect (CzIE), defined here as a cefazolin MIC at high inoculum (107 colony-forming units/mL) ≥16 mg/L in MSSA, has been associated with less favourable clinical outcomes. However, detection of this phenotype is challenging in the clinical microbiology laboratory. We previously described modification of a rapid nitrocefin test using ampicillin disks rather than ampicillin powder for induction of the Staphylococcus aureus β-lactamase (BlaZ). OBJECTIVE: Evaluate the performance of the modified rapid nitrocefin test in a blinded fashion using MSSA isolates recovered from patients with bacteraemia. METHODS: We evaluated 200 MSSA isolates recovered from Latin American (LA) and North American (NA) hospitals (67 and 133 from NA and LA, respectively). The CzIE was determined using the modified rapid nitrocefin test with ampicillin disks and compared with MIC determination at high inoculum (gold standard). All isolates were subjected to whole-genome sequencing on an Illumina Hi-Seq platform. Performance metrics were calculated for the complete dataset and according to specific BlaZ types. RESULTS: The prevalence of the CzIE was 53% (105/200). Compared with the gold standard, the modified nitrocefin rapid test had a sensitivity of 96% and a specificity of 91.6%, with an overall accuracy of 94%. There were no false-positive results among blaZ-negative MSSA strains. CONCLUSIONS: The modified nitrocefin rapid test exhibited a robust performance to detect the CzIE in isolates from the Americas. This methodology is inexpensive and can be implemented in clinical microbiology laboratories around the world, including those with limited resources.
3. CMTM4 promotes PD-L1-mediated macrophage apoptosis by enhancing STAT2 phosphorylation in sepsis.
CMTM4 expression increases in sepsis and drives macrophage apoptosis by enhancing STAT2 phosphorylation, which upregulates PD-L1; inhibiting CMTM4 reduced apoptosis in vitro and in vivo models. Multi-modal assays (immunofluorescence, WB, flow cytometry, ChIP-qPCR, Co-IP) support a CMTM4–STAT2–PD-L1 pathway as a mechanistic contributor to sepsis-induced immune cell loss.
Impact: Reveals a novel immune-regulatory axis linking CMTM4 to PD-L1 via STAT2, identifying a potential diagnostic and therapeutic target for modulating macrophage death in sepsis.
Clinical Implications: While preclinical, targeting CMTM4–STAT2–PD-L1 signaling could help preserve innate immune cells in sepsis; biomarkers from this axis might aid risk stratification of immune dysfunction.
Key Findings
- CMTM4 expression was upregulated in macrophages during sepsis in clinical samples and models.
- CMTM4 inhibition reduced macrophage apoptosis in vitro and in vivo.
- CMTM4 promotes PD-L1 expression by enhancing STAT2 phosphorylation (transcriptional regulation), not by direct binding to PD-L1.
- Multi-omics and biochemical assays (transcriptomics, ChIP-qPCR, Co-IP) corroborated the CMTM4–STAT2–PD-L1 pathway.
Methodological Strengths
- Use of clinical samples with complementary in vitro and in vivo models.
- Multiple orthogonal assays (IF, WB, flow cytometry, transcriptomics, ChIP-qPCR, Co-IP) supporting mechanism.
Limitations
- Preclinical study without interventional validation of therapeutic targeting in animal survival models.
- Generalizability across sepsis etiologies and human cell subsets remains to be established.
Future Directions: Test pharmacologic or genetic modulation of CMTM4/STAT2/PD-L1 in sepsis survival models; evaluate circulating biomarkers from this axis in patient cohorts for prognostication.
BACKGROUND: Macrophage apoptosis is a key contributor to the elimination of immune cells and increased susceptibility during sepsis. CKLF like MARVEL transmembrane domain containing 4 (CMTM4) is a membrane protein with four transmembrane domains. It has recently been implicated in the regulation of immune cell biological functions. However, its role in regulating macrophage apoptosis during sepsis has not been extensively studied. METHODS: Clinical samples were analyzed to determine CMTM4 expression levels and their correlation with clinical examination results. An in vitro model was developed using C57BL/6 mice and the THP-1 cell line. An immunofluorescence analysis was used to assess protein expression levels, apoptosis, and protein co-localization. Western blotting (WB) was used to measure protein expression levels, while flow cytometry was used to detect cell apoptosis. Transcriptomic sequencing was conducted to identify differentially expressed genes and to perform a functional enrichment analysis. Transcription factors were screened using databases. Chromatin immunoprecipitation, followed by quantitative PCR (ChIP-qPCR), was conducted to analyze protein-DNA interactions, and co-immunoprecipitation (Co-IP) was used to examine protein-protein interactions. RESULTS: CMTM4 expression in macrophages was upregulated in sepsis. The inhibition of CMTM4 expression reduced macrophage apoptosis. PD-L1 was identified as a key molecule regulated by CMTM4 in macrophage apoptosis. CMTM4 regulates PD-L1 by promoting the phosphorylation of its transcription factor, STAT2, rather than directly binding to PD-L1. CONCLUSION: In sepsis, CMTM4 facilitates PD-L1-dependent macrophage apoptosis by enhancing STAT2 phosphorylation. This discovery offers new insights for the diagnosis and treatment of sepsis.